APA

Wildemberg L. E. A., Neto L. V., Costa D. F., Nasciuti L. E., Takiya C. M., Alves L. M., Rebora A., Minuto F., Ferone D. & Gadelha M. R. (20130808). Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. : Journal of endocrinological investigation.

Chicago

Wildemberg L E A, Neto L V, Costa D F, Nasciuti L E, Takiya C M, Alves L M, Rebora A, Minuto F, Ferone D and Gadelha M R. 20130808. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. : Journal of endocrinological investigation.

Harvard

Wildemberg L. E. A., Neto L. V., Costa D. F., Nasciuti L. E., Takiya C. M., Alves L. M., Rebora A., Minuto F., Ferone D. and Gadelha M. R. (20130808). Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. : Journal of endocrinological investigation.

MLA

Wildemberg L E A, Neto L V, Costa D F, Nasciuti L E, Takiya C M, Alves L M, Rebora A, Minuto F, Ferone D and Gadelha M R. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. : Journal of endocrinological investigation. 20130808.